

# Jesus Yamamoto-Furusho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4907898/publications.pdf>

Version: 2024-02-01

143  
papers

3,393  
citations

159585

30  
h-index

182427

51  
g-index

154  
all docs

154  
docs citations

154  
times ranked

5018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of cytokines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 4280.	3.3	552
2	Immunoregulatory Pathways Involved in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2188-2193.	1.9	83
3	Rheumatic manifestations of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 5517.	3.3	80
4	Tumor necrosis factor- $\beta$ promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE). <i>Genes and Immunity</i> , 2001, 2, 363-366.	4.1	74
5	Intestinal Protozoa Infections among Patients with Ulcerative Colitis: Prevalence and Impact on Clinical Disease Course. <i>Digestion</i> , 2010, 82, 18-23.	2.3	73
6	Centaurin $\beta$ 1 Down-regulates Nucleotide-binding Oligomerization Domains 1- and 2-dependent NF- $\kappa$ B Activation. <i>Journal of Biological Chemistry</i> , 2006, 281, 36060-36070.	3.4	69
7	Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. <i>Cytokine</i> , 2015, 75, 389-402.	3.2	66
8	Further evidence of the role of HLA-DR4 in the genetic susceptibility to actinic prurigo. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 935-937.	1.2	63
9	Innate immunity in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 5577.	3.3	63
10	Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. <i>Cellular Signalling</i> , 2020, 72, 109636.	3.6	59
11	Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. <i>BMC Gastroenterology</i> , 2011, 11, 138.	2.0	58
12	IL-10 <sup>hi</sup> and IL-20 <sup>hi</sup> Expressing Epithelial and Inflammatory Cells are Increased in Patients with Ulcerative Colitis. <i>Journal of Clinical Immunology</i> , 2013, 33, 640-648.	3.8	58
13	Expression of interleukin (IL)-19 and IL-24 in inflammatory bowel disease patients: a cross-sectional study. <i>Clinical and Experimental Immunology</i> , 2014, 177, 64-75.	2.6	58
14	Novel genetic markers in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 5560.	3.3	55
15	Association of HLA-DR4 (DRB1*0404) With Human Papillomavirus Infection in Patients With Focal Epithelial Hyperplasia. <i>Archives of Dermatology</i> , 2004, 140, 1227-31.	1.4	54
16	HLA-DRB1 alleles encoding the $\beta$ 2-microglobulin epitope are associated with susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles encoding an aspartic acid at position 70 of the $\beta$ 2-chain are protective in Mexican mestizos. <i>Human Immunology</i> , 2004, 65, 262-269.	2.4	50
17	Inflammatory bowel disease therapy. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 187-193.	2.3	49
18	Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. <i>Human Immunology</i> , 2003, 64, 119-123.	2.4	48

#	ARTICLE	IF	CITATIONS
19	Basic and clinical aspects of osteoporosis in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 6156.	3.3	48
20	Interleukin 1 $\hat{I}^2$ (IL-1B) and IL-1 Antagonist Receptor (IL-1RN) Gene Polymorphisms are Associated With the Genetic Susceptibility and Steroid Dependence in Patients With Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 531-535.	2.2	48
21	Differential Expression of IL-36 Family Members and IL-38 by Immune and Nonimmune Cells in Patients with Active Inflammatory Bowel Disease. <i>BioMed Research International</i> , 2018, 2018, 1-12.	1.9	47
22	Basic and clinical aspects of osteoporosis in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 6156.	3.3	46
23	Clinical Epidemiology of Ulcerative Colitis in Mexico. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 221-224.	2.2	42
24	Peroxisome proliferator-activated receptor-gamma (PPAR- $\hat{I}^3$ ) expression is downregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 680-681.	1.9	40
25	Role of biological therapy for inflammatory bowel disease in developing countries. <i>Gut</i> , 2012, 61, 706-712.	12.1	39
26	Haplotype Distribution of Class II MHC Genes in Mexican Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 1998, 27, 373-376.	1.1	36
27	Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000â€“2017). <i>Medicine (United States)</i> , 2019, 98, e16291.	1.0	35
28	Polymorphisms in the promoter region of tumor necrosis factor alpha (TNF- $\hat{I}^{\pm}$ ) and the HLA-DRB1 locus in Mexican Mestizo patients with ulcerative colitis. <i>Immunology Letters</i> , 2004, 95, 31-35.	2.5	34
29	Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. <i>Human Immunology</i> , 2011, 72, 1029-1032.	2.4	33
30	Genetic factors associated with the development of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 5594.	3.3	31
31	Association of HLA-DRB1*16 with chronic discoid lupus erythematosus in Mexican mestizo patients. <i>Clinical and Experimental Dermatology</i> , 2007, 32, 435-438.	1.3	31
32	Crohnâ€™s disease: Innate immunodeficiency?. <i>World Journal of Gastroenterology</i> , 2006, 12, 6751.	3.3	31
33	Differential expression of occludin in patients with ulcerative colitis and healthy controls. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E1999.	1.9	30
34	Innovative therapeutics for inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2007, 13, 1893.	3.3	30
35	MDP-NOD2 stimulation induces HNP-1 secretion, which contributes to NOD2 antibacterial function. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 736-742.	1.9	29
36	Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Prevalence and factors associated with the presence of Abnormal Function Liver Tests in patients with ulcerative colitis. <i>Annals of Hepatology</i> , 2010, 9, 397-401.	1.5	28
38	HLA-DR6 (possibly DRB1*1301) is associated with susceptibility to Takayasu arteritis in Mexicans. <i>Heart and Vessels</i> , 1996, 11, 277-280.	1.2	27
39	Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico. <i>Mycopathologia</i> , 1997, 138, 137-141.	3.1	27
40	Escala de Ansiedad y Depresi3n Hospitalaria (HADS): Validaci3n en pacientes mexicanos con enfermedad inflamatoria intestinal. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2018, 41, 477-482.	0.5	27
41	Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E135-E136.	1.9	26
42	Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1823.	1.9	25
43	Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. <i>Immunology Letters</i> , 2016, 172, 79-83.	2.5	24
44	Interleukin 27 is up-regulated in patients with active inflammatory bowel disease. <i>Immunologic Research</i> , 2016, 64, 901-907.	2.9	23
45	Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2020, 2020, 1-11.	3.0	23
46	Peroxisome Proliferator-Activated Receptors Family Is Involved in the Response to Treatment and Mild Clinical Course in Patients with Ulcerative Colitis. <i>Disease Markers</i> , 2014, 2014, 1-7.	1.3	22
47	Diagn3stico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterolog3a De M3xico</i> , 2017, 82, 46-84.	0.2	22
48	Consenso mexicano para el diagn3stico y tratamiento de la colitis ulcerosa cr3nica idiop3tica. <i>Revista De Gastroenterolog3a De M3xico</i> , 2018, 83, 144-167.	0.2	22
49	Infliximab as a Rescue Therapy for Hospitalized Patients with Severe Ulcerative Colitis Refractory to Systemic Corticosteroids. <i>Digestive Surgery</i> , 2008, 25, 383-386.	1.2	20
50	Antinuclear antibodies: A marker associated with steroid dependence in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1039-1043.	1.9	20
51	Consenso mexicano sobre probi3ticos en gastroenterolog3a. <i>Revista De Gastroenterolog3a De M3xico</i> , 2017, 82, 156-178.	0.2	20
52	HLA-DR7 in Association with Chlorpromazine-induced Lupus Anticoagulant (LA). <i>Journal of Autoimmunity</i> , 1997, 10, 579-583.	6.5	19
53	Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. <i>Journal of Inflammation</i> , 2018, 15, 13.	3.4	19
54	HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. <i>European Journal of Neurology</i> , 2003, 10, 707-710.	3.3	17

#	ARTICLE	IF	CITATIONS
55	Association of HLA-DR3 and HLA-DR4 with Sinonasal Polyposis in Mexican Mestizos. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 135, 90-93.	1.9	17
56	Association of GIST and Somatostatinoma in a Patient With Type-1 Neurofibromatosis: Is There a Common Pathway?. <i>American Journal of Gastroenterology</i> , 2009, 104, 797-799.	0.4	17
57	Indoleamine 2,3-Dioxygenase: Expressing Cells in Inflammatory Bowel Disease—A Cross-Sectional Study. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	17
58	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the iSupport Therapy—Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018, 16, 522-528.	2.6	17
59	Interleukin 21 Expression is Increased in Rectal Biopsies from Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1090.	1.9	16
60	TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1267-1268.	1.9	16
61	HLA-DRB1*0101 is associated with the genetic susceptibility to develop lichen planus in the Mexican Mestizo population. <i>Archives of Dermatological Research</i> , 2007, 299, 405-407.	1.9	15
62	Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. <i>PLoS ONE</i> , 2020, 15, e0231988.	2.5	15
63	Comptype SC30 Is Associated With Susceptibility to Develop Ulcerative Colitis in Mexicans. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 178-179.	2.2	15
64	Genetic Markers Associated with Clinical Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2683-2695.	1.9	14
65	TRPV Subfamily (TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6) Gene and Protein Expression in Patients with Ulcerative Colitis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	2.2	14
66	Gene expression profiling of inflammatory cytokines in esophageal biopsies of different phenotypes of gastroesophageal reflux disease: a cross-sectional study. <i>BMC Gastroenterology</i> , 2021, 21, 201.	2.0	14
67	HLA-DRB1*04 is associated with the genetic susceptibility to develop vitiligo in Mexican patients with autoimmune thyroid disease. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 182-183.	1.2	13
68	Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis. <i>Immunology Letters</i> , 2013, 149, 50-53.	2.5	13
69	Association of the interleukin 15 (IL-15) gene polymorphisms with the risk of developing ulcerative colitis in Mexican individuals. <i>Molecular Biology Reports</i> , 2014, 41, 2171-2176.	2.3	13
70	The Transient Receptor Potential Vanilloid 1 Is Associated with Active Inflammation in Ulcerative Colitis. <i>Mediators of Inflammation</i> , 2018, 2018, 1-7.	3.0	13
71	Effect of Cis-palmitoleic acid supplementation on inflammation and expression of HNF4 $\beta$ , HNF4 $\alpha$ and IL6 in patients with ulcerative colitis. <i>Minerva Gastroenterology</i> , 2017, 63, 257-263.	0.5	13
72	Hospital Anxiety and Depression Scale (HADS): Validation in Mexican patients with inflammatory bowel disease. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2018, 41, 477-482.	0.1	12

#	ARTICLE	IF	CITATIONS
73	Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: Cross-sectional study. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12962.	2.7	12
74	Emerging therapeutic options in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 8242-8261.	3.3	12
75	Cytomegalovirus Infection in Patients Who Required Colectomy for Toxic Megacolon or Severe Steroid-Refractory Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 867-868.	2.3	11
76	High Gene Expression of MDR1 (ABCB1) is Associated with Medical Treatment Response and Long-Term Remission in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 541-542.	1.9	11
77	Gene expression of carnitine organic cation transporters 1 and 2 (OCTN) is downregulated in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2205-2206.	1.9	11
78	Evaluation of diet pattern related to the symptoms of mexican patients with Ulcerative Colitis (UC): through the validity of a questionnaire. <i>Nutrition Journal</i> , 2015, 14, 25.	3.4	11
79	Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. <i>Digestive and Liver Disease</i> , 2020, 52, 869-877.	0.9	11
80	Expression of TOB/BTG family members in patients with inflammatory bowel disease. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13004.	2.7	11
81	HLA Study on Two Mexican Mestizo Families with Autoimmune Thyroid Disease. <i>Autoimmunity</i> , 2002, 35, 265-269.	2.6	10
82	New treatment options in the management of IBD – focus on colony stimulating factors. <i>Biologics: Targets and Therapy</i> , 2008, 2, 501.	3.2	10
83	Growth factors as treatment for inflammatory bowel disease: A concise review of the evidence toward their potential clinical utility. <i>Saudi Journal of Gastroenterology</i> , 2009, 15, 208.	1.1	10
84	Validación de un nuevo Índice integral de enfermedad para evaluar el grado de actividad en pacientes mexicanos con colitis ulcerosa: un estudio de cohorte prospectivo. <i>Revista De Gastroenterología De México</i> , 2019, 84, 317-325.	0.2	10
85	Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 206-213.	0.5	10
86	HLA-DRB1 alleles are associated with the clinical course of disease and steroid dependence in Mexican patients with ulcerative colitis. <i>Colorectal Disease</i> , 2010, 12, 1231-1235.	1.4	9
87	Gene expression of solute carrier family 9 (Sodium/Hydrogen Exchanger) 3, (SLC9A3) is downregulated in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1197-1198.	1.9	9
88	Reduced expression of mucin 9 (MUC9) in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E601.	1.9	9
89	Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 197-204.	0.7	9
90	Role of the HLA-DQ locus in the development of chronic gastritis and gastric carcinoma in Mexican patients. <i>World Journal of Gastroenterology</i> , 2006, 12, 7762.	3.3	9

#	ARTICLE	IF	CITATIONS
91	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
92	Distinguishing Between Anti-Neutrophil Cytoplasmic Antibody Patterns in Inflammatory Bowel Disease: Is the "Atypical Pattern" Adding More Information?. <i>American Journal of Gastroenterology</i> , 2009, 104, 1854-1855.	0.4	8
93	Factors that influence outcome in non-invasive and invasive treatment in polycystic liver disease patients. <i>World Journal of Gastroenterology</i> , 2008, 14, 3195.	3.3	8
94	HLA-DRB1*08 allele may help to distinguish between type 1 diabetes mellitus and type 2 diabetes mellitus in Mexican children. <i>Pediatric Diabetes</i> , 2007, 8, 5-10.	2.9	7
95	Role of the interleukin 24 in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2209-2210.	1.9	7
96	Quantification of low expressed SCD1 gene in colonic mucosa from patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E155.	1.9	7
97	Leiden V Factor and Spastic Cerebral Palsy in Mexican Children. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 978-980.	0.7	7
98	Frequency, Clinical Features and Factors Associated with Pouchitis after Proctocolectomy with ileo-Pouch-Anal Anastomosis in Patients with Ulcerative Colitis: A Latin-American Country Retrospective-Cohort Study. <i>Digestive Surgery</i> , 2015, 32, 489-495.	1.2	7
99	Association of the HLA-DRB1*0701 allele with perinuclear anti-neutrophil cytoplasmic antibodies in Mexican patients with severe ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2006, 12, 1617.	3.3	7
100	Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: Experience in a Mexican institution. <i>World Journal of Gastroenterology</i> , 2006, 12, 3406.	3.3	7
101	Expression of HNF4 $\beta$ is downregulated in patients with active ulcerative colitis (UC) compared to UC patients in remission and healthy controls. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E91.	1.9	6
102	High Gene Expression of CXCL8 Is Associated with the Presence of Extraintestinal Manifestations and Long-term Disease in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E22-E23.	1.9	6
103	Joint involvement in Mexican patients with ulcerative colitis: a hospital-based retrospective study. <i>Clinical Rheumatology</i> , 2018, 37, 677-682.	2.2	6
104	Intestinal production of secreted protein acidic and rich in cysteine (SPARC) in patients with ulcerative colitis. <i>Immunobiology</i> , 2021, 226, 152095.	1.9	6
105	Differential Cytokine Expression in the Duodenum and Rectum of Children with Non-Immunoglobulin E-Mediated Cow's Milk Protein Allergy. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3769-3775.	2.3	6
106	Mild Clinical Behaviour of Crohn Disease in Elderly Patients in a Latin American Country: A Case-Control Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 435-439.	1.9	5
107	Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-5.	1.5	5
108	Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. <i>Annals of Hepatology</i> , 2010, 9, 397-401.	1.5	5

#	ARTICLE	IF	CITATIONS
109	Interleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E50-E51.	1.9	4
110	Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). <i>Revista De Gastroenterología De México</i> , 2017, 82, 134-155.	0.2	4
111	Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México. <i>Revista De Gastroenterología De México</i> , 2018, 83, 414-423.	0.2	4
112	Synthesis of Interleukin-10 in Patients with Ulcerative Colitis and <i>Helicobacter pylori</i> Infection. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	1.5	4
113	Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets. <i>Current Immunology Reviews</i> , 2013, 9, 86-92.	1.2	4
114	Diagnostic Delay of Inflammatory Bowel Disease Is Significantly Higher in Public versus Private Health Care System in Mexican Patients. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 72-80.	1.9	4
115	Gene and protein expression of centaurin beta 1 (CENTB1) are up-regulated in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e238-e239.	1.3	3
116	Polimorfismos genéticos de interleucina-22 en pacientes con colitis ulcerosa. <i>Revista De Gastroenterología De México</i> , 2016, 81, 86-90.	0.2	3
117	Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 711-718.	0.5	3
118	AKAP12/Gravin is over-expressed in patients with ulcerative colitis. <i>Immunologic Research</i> , 2021, 69, 429-435.	2.9	3
119	Rheumatoid Arthritis Associated With Pemphigus Foliaceus in a Patient Not Taking Penicillamine. <i>Skinmed</i> , 2007, 6, 252-254.	0.0	2
120	Increased expression of discs large homolog 5 gene (DLG5) in ulcerative colitis patients compared to healthy individuals. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1639.	1.9	2
121	Mortality and Hospitalizations in Mexican Patients with Inflammatory Bowel Disease: Results from a Nationwide Health Registry. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-8.	1.9	2
122	Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 200-204.	1.9	2
123	ABCC7/CFTR Expression Is Associated with the Clinical Course of Ulcerative Colitis Patients. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-7.	1.5	2
124	Depression and Anxiety Disorders Impact in the Quality of Life of Patients with Inflammatory Bowel Disease. <i>Psychiatry Journal</i> , 2021, 2021, 1-7.	1.5	2
125	Su1257 The Gene Expression of SPARC in the Colonic Mucosa Is Associated With Histological Activity in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 148, S-453.	1.3	1
126	Mo1712 Role of Interleukin 27 (IL-27) in the Colonic Mucosa of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 148, S-692.	1.3	1

#	ARTICLE	IF	CITATIONS
127	Role of IL-38 and its Antagonist in Patients with Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S762.	1.3	1
128	Evaluaci3n del esquema de vacunaci3n y cuidados con relaci3n al seguimiento y tratamiento de los pacientes con enfermedad inflamatoria intestinal. <i>Revista De Gastroenterolog3a De M3xico</i> , 2019, 84, 11-17.	0.2	1
129	Mental Health Factors Associated With Fatigue in Mexican Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, Publish Ahead of Print, 609-614.	2.2	1
130	Independent Associations of the HLA-B27 Antigen and the Complement Haplotype SC21 in Chronic Anterior Uveitis. <i>Ocular Immunology and Inflammation</i> , 1996, 4, 203-206.	1.8	0
131	Genetic Susceptibility in Inflammatory Bowel Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010, 8, 149-159.	0.8	0
132	Differential Expression of Disc Large Homologue 5 (DLG5) and Carnitine Organic Cation Transporter (OCTN) Genes in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-422.	1.3	0
133	Factors Associated With Use of Azathioprine in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-791.	1.3	0
134	Sa1848 IL34 and IL36 Family Expressing Cytotoxic T cells and Plasmacytoid Dendritic Cells are Increased in Patients With Active Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S379-S380.	1.3	0
135	Mo1930 Transcriptome Analysis of Immune Innate Response Genes in the Colonic Mucosa from Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S819.	1.3	0
136	Tu1981 The Oxido-reductases Enzymes (TDO2 and SOD2) in Colonic Mucosa are Markers Associated with Histological Activity and Clinical Course in Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, S996.	1.3	0
137	Expression of Genes Associated with Inflammation in Biopsies of Esophageal Mucosa of different Phenotypes of Gastroesophageal Reflux Disease. <i>Gastroenterology</i> , 2017, 152, S237.	1.3	0
138	Prevalence of mental disorder and impact on quality of life in inflammatory bowel disease. <i>Gastroenterolog3a Y Hepatolog3a (English Edition)</i> , 2021, 44, 206-213.	0.1	0
139	Changes in chronic idiopathic ulcerative colitis epidemiological pattern in Mexico in a tertiary care hospital. <i>Gaceta Medica De Mexico</i> , 2023, 157, 147-153.	0.3	0
140	Validaci3n de Belief Medicines Questionnaire y Self-efficacy for Appropriate Medication Use Scale para medir adherencia al tratamiento farmacol3gico en pacientes con enfermedad inflamatoria intestinal. <i>Gaceta Medica De Mexico</i> , 2019, 155, 124-129.	0.3	0
141	813â€ŸIncidence and Indicators of Suboptimal Response to Tumor Necrosis Factor Antagonist Therapy in Inflammatory Bowel Disease in Newly Industrialized Countries: Results From the EXPLORE Study. <i>American Journal of Gastroenterology</i> , 2019, 114, S470-S470.	0.4	0
142	Association of dietary fiber consumption with disease activity in ulcerative colitis: An exploratory study in the Mexican population. <i>Gaceta Medica De Mexico</i> , 2022, 158, 41-47.	0.3	0
143	Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. <i>Gastroenterolog3a Y Hepatolog3a (English Edition)</i> , 2021, 44, 711-718.	0.1	0